Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium

References

• Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours, F. A Tavassoli, P Devilee. IARC Press, Lyon 2003
   Google Scholar
• Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67
   PubMed Web of Science ®Google Scholar
• Kinzler K. W., Vogelstein B. Cancer‐susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 761, 763
   PubMed Web of Science ®Google Scholar
• Spruck C. H., 3rd., Ohneseit P. F., Gonzalez‐Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784–8
   PubMed Web of Science ®Google Scholar
• Kinzler K. W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159–70
   PubMed Web of Science ®Google Scholar
• Perucho M. Microsatellite instability: the mutator that mutates the other mutator. Nat Med 1996; 2: 630–1
   PubMed Web of Science ®Google Scholar
• Bennicelli J. L., Barr F. G. Chromosomal translocations and sarcomas. Curr Opin Oncol 2002; 14: 412–9
   PubMed Web of Science ®Google Scholar
• Schneider‐Stock R., Walter H., Radig K., et al. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol 1998; 124: 532–40
   PubMed Web of Science ®Google Scholar
• Lax S. F., Kurman R. J. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997; 81: 228–32
   PubMedGoogle Scholar
• Sherman M. E., Bur M. E., Kurman R. J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26: 1268–74
   PubMed Web of Science ®Google Scholar
• Matias‐Guiu X., Catasus L., Bussaglia E., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569–77
   PubMed Web of Science ®Google Scholar
• Salvesen H. B., Akslen L. A. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Apmis 2002; 110: 673–89
   PubMed Web of Science ®Google Scholar
• Lax S. F., Pizer E. S., Ronnett B. M., Kurman R. J. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki‐67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29: 551–8
   PubMed Web of Science ®Google Scholar
• Sherman M. E., Sturgeon S., Brinton L. A., et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997; 10: 963–8
   PubMed Web of Science ®Google Scholar
• Enriori C. L., Reforzo‐Membrives J. Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review. Gynecol Oncol 1984; 17: 1–21
   PubMed Web of Science ®Google Scholar
• Potischman N., Hoover R. N., Brinton L. A., et al. Case‐control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88: 1127–35
   PubMed Web of Science ®Google Scholar
• Weiderpass E., Adami H. O., Baron J. A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7
   PubMed Web of Science ®Google Scholar
• Sherman M. E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13: 295–308
   PubMed Web of Science ®Google Scholar
• Ambros R. A., Sherman M. E., Zahn C. M., Bitterman P., Kurman R. J. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26: 1260–7
   PubMed Web of Science ®Google Scholar
• Abeler V. M., Vergote I. B., Kjorstad K. E., Trope C. G. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996; 78: 1740–7
   PubMed Web of Science ®Google Scholar
• Cirisano F. D., Jr., Robboy S. J., Dodge R. K., et al. The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000; 77: 55–65
   PubMed Web of Science ®Google Scholar
• Mutter G. L., Lin M. C., Fitzgerald J. T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924–30
   PubMed Web of Science ®Google Scholar
• Mutter G. L. Pten, a protean tumor suppressor. Am J Pathol 2001; 158: 1895–8
   PubMed Web of Science ®Google Scholar
• Duggan B. D., Felix J. C., Muderspach L. I., Tsao J. L., Shibata D. K. Early mutational activation of the c‐Ki‐ras oncogene in endometrial carcinoma. Cancer Res 1994; 54: 1604–7
   PubMed Web of Science ®Google Scholar
• Levine R. L., Cargile C. B., Blazes M. S., van Rees B., Kurman R. J., Ellenson L. H. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998; 58: 3254–8
   PubMed Web of Science ®Google Scholar
• Mutter G. L., Baak J. P., Crum C. P., Richart R. M., Ferenczy A., Faquin W. C. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190: 462–9
   PubMed Web of Science ®Google Scholar
• Riethdorf L., Begemann C., Riethdorf S., Milde‐Langosch K., Loning T. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature‐gradient gel electrophoresis. Virchows Arch 1996; 428: 47–51
   PubMed Web of Science ®Google Scholar
• Lax S. F., Kendall B., Tashiro H., Slebos R. J., Hedrick L. The frequency of p53, K‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88: 814–24
   PubMed Web of Science ®Google Scholar
• Burks R. T., Kessis T. D., Cho K. R., Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene 1994; 9: 1163–6
   PubMed Web of Science ®Google Scholar
• Caduff R. F., Johnston C. M., Svoboda Newman S. M., Poy E. L., Merajver S. D., Frank T. S. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996; 148: 1671–8
   PubMed Web of Science ®Google Scholar
• Risinger J. I., Berchuck A., Kohler M. F., Watson P., Lynch H. T., Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53: 5100–3
   PubMed Web of Science ®Google Scholar
• Salvesen H. B., MacDonald N., Ryan A., et al. Methylation of hMLH1 in a population‐based series of endometrial carcinomas. Clin Cancer Res 2000; 6: 3607–13
   PubMed Web of Science ®Google Scholar
• Esteller M., Levine R., Baylin S. B., Ellenson L. H., Herman J. G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17: 2413–7
   PubMed Web of Science ®Google Scholar
• Esteller M., Catasus L., Matias Guiu X., et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767–72
   PubMed Web of Science ®Google Scholar
• Sumoi R., Hakala Ala Pietila T., Leminen A., Mecklin J. P., Lehtovirta P. Hereditary aspects of endometrial adenocarcinoma. Int J Cancer 1995; 62: 132–7
   PubMed Web of Science ®Google Scholar
• Vasen H. F., Watson P., Mecklin J. P., et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994; 14: 1675–8
   PubMed Web of Science ®Google Scholar
• Watson P., Vasen H. F., Mecklin J. P., Jarvinen H., Lynch H. T. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516–20
   PubMed Web of Science ®Google Scholar
• Ioffe O. B., Papadimitriou J. C., Drachenberg C. B. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl‐2 and c‐erbB‐2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998; 29: 1150–9
   PubMed Web of Science ®Google Scholar
• Salvesen H. B., Das S., Akslen L. A. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000; 6: 153–9
   PubMed Web of Science ®Google Scholar
• Rolitsky C. D., Theil K. S., McGaughy V. R., Copeland L. J., Niemann T. H. HER‐2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999; 18: 138–43
   PubMed Web of Science ®Google Scholar
• Tashiro H., Isacson C., Levine R., Kurman R. J., Cho K. R., Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177–85
   PubMed Web of Science ®Google Scholar
• Holcomb K., Delatorre R., Pedemonte B., McLeod C., Anderson L., Chambers J. E‐cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002; 100: 1290–5
   PubMed Web of Science ®Google Scholar
• Moreno‐Bueno G., Hardisson D., Sarrio D., et al. Abnormalities of E‐ and P‐cadherin and catenin (beta‐, gamma‐catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003; 199: 471–8
   PubMed Web of Science ®Google Scholar
• Halperin R., Zehavi S., Habler L., Hadas E., Bukovsky I., Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001; 22: 122–6
   PubMed Web of Science ®Google Scholar
• Tashiro H., Blazes M. S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935–40
   PubMed Web of Science ®Google Scholar
• Tashiro H., Lax S. F., Gaudin P. B., Isacson C., Cho K. R., Hedrick L. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997; 150: 75–9
   PubMed Web of Science ®Google Scholar
• An H. J., Logani S., Isacson C., Ellenson L. H. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004; 17: 530–7
   PubMed Web of Science ®Google Scholar
• Lax S. F., Abeler V. M., Regitnig P. Molecular genetic analysis of endometrial carcinoma: Evidence for 2 genetically distinctive entities. Virchows Arch 2001; 439: 247
   Google Scholar
• Maxwell G. L., Chandramouli G. V., Dainty L., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005; 11: 4056–66
   PubMed Web of Science ®Google Scholar
• Moreno‐Bueno G., Sanchez‐Estevez C., Cassia R., et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003; 63: 5697–702
   PubMed Web of Science ®Google Scholar
• Risinger J. I., Maxwell G. L., Chandramouli G. V., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003; 63: 6–11
   PubMed Web of Science ®Google Scholar
• Zorn K. K., Bonome T., Gangi L., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005; 11: 6422–30
   PubMed Web of Science ®Google Scholar
• Santin A. D., Zhan F., Cane S., et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005; 92: 1561–73
   PubMed Web of Science ®Google Scholar
• Risinger J. I., Maxwell G. L., Chandramouli G. V., et al. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res 2005; 65: 5031–7
   PubMed Web of Science ®Google Scholar
• Shedden K. A., Kshirsagar M. P., Schwartz D. R., et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005; 11: 2123–31
   PubMed Web of Science ®Google Scholar
• McCluggage W. G., Sumathi V. P., Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001; 39: 273–8
   PubMed Web of Science ®Google Scholar
• Sabini G., Chumas J. C., Mann W. J. Steroid hormone receptors in endometrial stromal sarcomas. A biochemical and immunohistochemical study. Am J Clin Pathol 1992; 97: 381–6
   PubMed Web of Science ®Google Scholar
• Tosi P., Sforza V., Santopietro R. Estrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma. Obstet Gynecol 1989; 73: 75–8
   PubMed Web of Science ®Google Scholar
• Reich O., Regauer S., Urdl W., Lahousen M., Winter R. Expression of oestrogen and progesterone receptors in low‐grade endometrial stromal sarcomas. Br J Cancer 2000; 82: 1030–4
   PubMed Web of Science ®Google Scholar
• Moinfar F., Regitnig P., Tabrizi A. D., Denk H., Tavassoli F. A. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch 2004; 444: 410–4
   PubMed Web of Science ®Google Scholar
• Amant F., Schurmans K., Steenkiste E., et al. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol 2004; 93: 680–5
   PubMed Web of Science ®Google Scholar
• Koontz J. I., Soreng A. L., Nucci M., et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 2001; 98: 6348–53
   PubMed Web of Science ®Google Scholar
• Hrzenjak A., Moinfar F., Tavassoli F. A., et al. JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular analysis by reverse transcriptase‐polymerase chain reaction optimized for paraffin‐embedded tissue. J Mol Diagn 2005; 7: 388–95
   PubMed Web of Science ®Google Scholar
• Huang H. Y., Ladanyi M., Soslow R. A. Molecular detection of JAZF1‐JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence for genetic heterogeneity. Am J Surg Pathol 2004; 28: 224–32
   PubMed Web of Science ®Google Scholar
• Micci F., Walter C. U., Teixeira M. R., et al. Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet Cytogenet 2003; 144: 119–24
   PubMedGoogle Scholar
• Tallini G., Vanni R., Manfioletti G., et al. HMGI‐C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI‐C and HMGI(Y) genes. Lab Invest 2000; 80: 359–69
   PubMed Web of Science ®Google Scholar
• Gunawan B., Schulten H. J., Fuzesi L. Identification of a BAC clone overlapping the t(6p12.3) breakpoint in the cell line ESS‐1 derived from an endometrial stromal sarcoma. Cancer Genet Cytogenet 2003; 147: 84–6
   PubMedGoogle Scholar
• Micci F., Panagopoulos I., Bjerkehagen B., Heim S. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 2006; 66: 107–12
   PubMed Web of Science ®Google Scholar
• Halbwedl I., Ullmann R., Kremser M. L., et al. Chromosomal alterations in low‐grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization. Gynecol Oncol 2005; 97: 582–7
   PubMed Web of Science ®Google Scholar
• Moinfar F., Kremser M. L., Man Y. G., Zatloukal K., Tavassoli F. A., Denk H. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal‐appearing endometrial and myometrial tissues. Gynecol Oncol 2004; 95: 662–71
   PubMed Web of Science ®Google Scholar
• Blom R., Malmstrom H., Guerrieri C. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm‐2 analysis of 17 cases. Int J Gynecol Cancer 1999; 98–104, 9
   PubMed Web of Science ®Google Scholar
• Amant F., Dorfling C. M., Dreyer L., Vergote I., Lindeque B. G., Van Rensburg E. J. Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer 2001; 11: 218–23
   PubMed Web of Science ®Google Scholar
• Hrzenjak A., Tippl M., Kremser M. L., et al. Inverse correlation of secreted frizzled‐related protein 4 and beta‐catenin expression in endometrial stromal sarcomas. J Pathol 2004; 204: 19–27
   PubMed Web of Science ®Google Scholar
• Bitterman P., Chun B., Kurman R. J. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990; 14: 317–28
   PubMed Web of Science ®Google Scholar
• Wada H., Enomoto T., Fujita M., et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997; 57: 5379–85
   PubMed Web of Science ®Google Scholar
• Fujii H., Yoshida M., Gong Z. X., et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000; 60: 114–20
   PubMed Web of Science ®Google Scholar
• Liu F. S., Kohler M. F., Marks J. R., Bast R. C., Jr., Boyd J., Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994; 83: 118–24
   PubMed Web of Science ®Google Scholar
• Taylor N. P., Zighelboim I., Huettner P. C., et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006; 19: 1333–8
   PubMed Web of Science ®Google Scholar
• Blom R., Guerrieri C., Stal O., Malmstrom H., Sullivan S., Simonsen E. Malignant mixed Mullerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm‐2 analysis of 44 cases. Gynecol Oncol 1998; 68: 18–24
   PubMed Web of Science ®Google Scholar
• Swisher E. M., Gown A. M., Skelly M., et al. The expression of epidermal growth factor receptor, HER‐2/Neu, p53, and Ki‐67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996; 60: 81–8
   PubMed Web of Science ®Google Scholar
• Robinson‐Bennett B., Belch R. Z., Han A. C. Loss of p16 in recurrent malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006; 16: 1354–7
   PubMed Web of Science ®Google Scholar
• Blom R., Guerrieri C. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm‐2 analysis of 11 cases. Int J Gynecol Cancer 1999; 9: 37–43
   PubMed Web of Science ®Google Scholar